Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Spero Therapeutics
Biotech
Spero pivots to I&I via $1.1B deal with Innovent antibody
Spero Therapeutics is also announcing a $105 million raise from Healthcare Royalty backed by the sales of its recently-approved antibiotic Utebzi.
Will Maddox
Jul 14, 2026 6:00am
Former Spero execs fined by SEC over antibiotic efficacy claims
Jan 20, 2026 11:34am
GSK unveils pivotal data on oral antibiotic ahead of FDA filing
Oct 21, 2025 10:55am
GSK's bet on rejected UTI antibiotic pays off with phase 3 win
May 28, 2025 8:42am
Scholar Rock rocks the boat with new execs—Chutes & Ladders
May 2, 2025 8:30am
Spero halts development on another antibiotic
Mar 28, 2025 7:05am
